Manufacturing automation within the supply chain to ensure patient safety

供应链内的制造自动化确保患者安全

• 批准号: EP/N508937/1
• 负责人: John Ahmet Erkoyuncu
• 金额: $ 15.96万
• 依托单位: CRANFIELD UNIVERSITY
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FN508937%2F1
• 关键词: Manufacturing; automation; within; supply; chain

The cell therapy industry is offering huge opportunities to transform the way healthcare is delivered. However, the currentamount of manufactured goods is limited and the manufacturing processes require drastic transformation to be able torespond to the potential demand. This proposal will aim to create a demonstrator that allows flexible manufacturing byautomating the storage and retrieval of sample vials from multiple large capacity Cryogenic storage devices. Adopting thistechnology / solution requires the cell therapy sector to develop an integrated supply chain to enhance the number ofmanufactured goods. The current project will first stabilise and subsequently grow robust pharmaceutical supply chains.In order to achieve this, the project will develop and implement novel rapid prototyping and manufacturing capability atFisher Bioservices. This design-led approach will reduce risk in the early stages of the development process, therebydramatically improving attrition rates and return on investment. The company will be recognised as leading thetransformation of developing cell therapy goods. The benefits are not limited to the company, its clients and supply chainpartners but will be realised across the whole value chain, including patients and wider society.Cranfield's main role focuses on investigate the improvement options to address the bottlenecks identified. This will lookinto developing tools and processes improving the manufacturing and supply chain. In line with the main aim of this WP,the following objectives are defined:1. Review suitable simulation approaches (Linear Optimisation, Discrete Event, Agent Based, and System Dynamics). Thiswill incorporate recent research in Gene Therapy, Aerospace and DefenceManufacturing (which are relatively low-volume, highly advanced technological manufacturing)2. Design and develop computerised simulation models to optimise the manufacturing (and supply chain) workflows. Thiswill involve using commercial off the shelf software packages and bespoketools developed for improving decisions in automation.3. Develop an innovation roadmap to embed the findings from the simulation models which will feed into WP3(DEVELOPMENT OF A MODULAR INTEGRATED AUTOMATED CRYOGENIC STORAGEARCHITECTURE) and WP 4 (NEXT GENERATION FACILITY)4. Validate the results and findings from simulation modelling with the real system. This can be done by multi-expertworkshops and comparisons with historical dataCranfield University will be involved across the WPs. Furthermore, WP 2 will be contributing to other WPs as coveredbelow:1. Based on the scope of work defined in WP1 (ASSESSMENT OF CURRENT MANUAL SYSTEMS), Cranfield Universitywill work closely with the Cell Therapy Catapult and others to collaborativelyconduct the review and gain knowledge from WP12. WP3 to provide relevant data required to develop simulation models (e.g. type of automation, degree of automation,cost of automation)3. WP4 to provide relevant data required to design the proposed production system4. Specific outputs to WP3 include various Decision making toolsets to identify where and how automation can be applied,what time and cost savings can be achieved through automation, what is the future supply chain going to look like. Casereports for industrial validations demonstrating the benefits of automation strategy using simulation modelling.5. Specific outputs to WP4 include optimised process configurations for FBS manufacturing supply chains6. From time to time the project partners need to validate the model developed and provide feedback. Validation to happen in 2 stages:a. To check of the model developed confirms to the real system (to be done by FBS)b. To check if the results from simulations are consistent with the initial assessment and meets the targets (to be done byFBS and Cell Therapy Catapult)

细胞治疗行业正在提供巨大的机会来改变医疗保健的交付方式。然而，目前的制成品数量是有限的，制造过程需要剧烈的转变，以能够响应潜在的需求。该提案旨在创建一个演示器，通过自动化存储和检索来自多个大容量低温存储设备的样品瓶来实现灵活的制造。采用这种技术/解决方案需要细胞治疗部门开发一个集成的供应链，以增加制成品的数量。目前的项目将首先稳定并随后发展强大的药品供应链。为了实现这一目标，该项目将在fisher生物服务公司开发和实施新的快速原型和制造能力。这种以设计为主导的方法将降低开发过程早期阶段的风险，从而显著提高流失率和投资回报率。该公司将被认为是引领细胞治疗产品开发转型的领军企业。这些好处不仅限于公司、其客户和供应链合作伙伴，还将在整个价值链中实现，包括患者和更广泛的社会。克兰菲尔德的主要职责是调查改进方案，以解决已确定的瓶颈问题。这将着眼于开发工具和流程，以改善制造和供应链。根据本工作计划的主要目的，定义了以下目标：1。回顾合适的仿真方法（线性优化，离散事件，基于代理和系统动力学）。这将包括最近在基因治疗、航空航天和国防制造（这是相对小批量、高度先进的技术制造）方面的研究。设计和开发计算机模拟模型，以优化制造（和供应链）工作流程。这将涉及使用商业现成的软件包和定制的工具，这些工具是为改进自动化决策而开发的。制定创新路线图，将仿真模型的发现嵌入到WP3（模块化集成自动化低温存储架构的开发）和WP 4（下一代设施）中。用实际系统验证仿真建模的结果和发现。这可以通过多专家研讨会和与历史数据的比较来完成。格兰菲尔德大学将参与整个WPs。此外，WP 2将为下文所述的其他WP做出贡献：根据WP1（当前手动系统评估）中定义的工作范围，克兰菲尔德大学将与细胞治疗弹射器和其他机构密切合作，共同进行审查并从WP12中获取知识。WP3提供开发仿真模型所需的相关数据（如自动化类型、自动化程度、自动化成本）WP4提供设计拟议生产系统所需的相关数据。WP3的具体输出包括各种决策制定工具集，以确定自动化可以在何处以及如何应用，通过自动化可以节省多少时间和成本，未来的供应链将是什么样子。用于工业验证的案例报告，展示了使用仿真建模的自动化策略的好处。WP4的具体输出包括FBS制造供应链的优化工艺配置6。项目合作伙伴需要不时地验证开发的模型并提供反馈。验证将分两个阶段进行：验证所开发的模型与实际系统的一致性（由FBS完成）。检查模拟结果是否与初始评估一致，是否符合目标（由fbs和Cell Therapy Catapult完成）

项目成果

An effective uncertainty based framework for sustainable industrial product-service system transformation

• DOI: 10.1016/j.jclepro.2018.09.182
• 发表时间: 2019-01
• 期刊: Journal of Cleaner Production
• 影响因子: 11.1
• 作者: J. Erkoyuncu;R. Roy;E. Shehab;C. Durugbo;Samir Khan;P. Datta

A modular hybrid simulation framework for complex manufacturing system design

用于复杂制造系统设计的模块化混合仿真框架

• DOI: 10.1016/j.simpat.2019.02.002
• 发表时间: 2019
• 期刊: Simulation Modelling Practice and Theory
• 影响因子: 4.2
• 作者: Farsi M

A framework to estimate the cost of No-Fault Found events

估算无故障事件成本的框架

• DOI: 10.1016/j.ijpe.2015.12.013
• 发表时间: 2016
• 期刊: International Journal of Production Economics
• 影响因子: 12
• 作者: Ahmet Erkoyuncu J